Evaluation of the Effect of a Combination of Plants to Regulate Mood

NCT ID: NCT06138470

Last Updated: 2025-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-30

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to confirm by a randomized double-blind controlled study the interest of a combination of saffron (Saffr'Activ®) and scutellaria (Scutell'up®) on the regulation of mood.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mood Regulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saffron extract

Group Type ACTIVE_COMPARATOR

Saffron extract

Intervention Type DIETARY_SUPPLEMENT

Food supplements are taken during 6 weeks by healthy volunteers

Scutellaria baicalensis extract

Group Type ACTIVE_COMPARATOR

Scutellaria baicalensis extract

Intervention Type DIETARY_SUPPLEMENT

Food supplements are taken during 6 weeks by healthy volunteers

Saffron and Scutellaria baicalensis extract

Group Type ACTIVE_COMPARATOR

Saffron and Scutellaria baicalensis extract

Intervention Type DIETARY_SUPPLEMENT

Food supplements are taken during 6 weeks by healthy volunteers

Placebo (maltodextrin)

Group Type PLACEBO_COMPARATOR

Placebo (maltodextrin)

Intervention Type DIETARY_SUPPLEMENT

Food supplements are taken during 6 weeks by healthy volunteers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saffron extract

Food supplements are taken during 6 weeks by healthy volunteers

Intervention Type DIETARY_SUPPLEMENT

Scutellaria baicalensis extract

Food supplements are taken during 6 weeks by healthy volunteers

Intervention Type DIETARY_SUPPLEMENT

Saffron and Scutellaria baicalensis extract

Food supplements are taken during 6 weeks by healthy volunteers

Intervention Type DIETARY_SUPPLEMENT

Placebo (maltodextrin)

Food supplements are taken during 6 weeks by healthy volunteers

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Woman or man, aged of 18 to 75 years;
* Participant presenting a depressive episode, according to the DSM-5 definition;
* Participant presenting a BDI ≥ 14 and ≤ 28 at the inclusion, corresponding to mild to moderate symptoms;
* Participant with a recent episode of depression (less than 2 years), not managed by antidepressant or psychotherapeutic treatment;
* Participant with a current depressive disorder not requiring, in the investigator's opinion, the initiation of antidepressant medication;
* Provision of signed and dated informed consent form;
* Stated willingness to comply with all study procedures and availability for the duration of the study;
* French speaker.

Exclusion Criteria

* Participant with a depressive disorder of another nature or any other mental pathology (schizophrenia, bipolarity, addiction to alcohol or drugs...);
* Participant at risk of suicide (determined by the Investigator, or HAMD item 3 score \> 2) or having made a suicide attempt in the last 5 years;
* Participant with depression for more than 2 years;
* Participant undergoing psychotropic treatment (current or in the month prior to inclusion) (neuroleptic, anxiolytic, hypnotic);
* Participant with a serious health problem for which the Investigator considers that it is not in the participant's interest to participate in the study;
* Participant using products containing piperine or millpertuis, or having a known effect on mood within the last 4 weeks;
* Pregnant or breastfeeding women, or those planning to become pregnant within the next 8 weeks;
* Participant with an allergy or contraindication to any component of the study drug;
* Participant unable to understand study information (mental or linguistic disability);
* Participant who is participating or has participated in the previous month in another clinical trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université Catholique de Louvain

OTHER

Sponsor Role collaborator

Comercial Quimica Masso, S.A

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Valérie Dormal, PhD

Role: STUDY_CHAIR

Université Catholique de Louvain

Louise Deldicque, Pr

Role: STUDY_DIRECTOR

Université Catholique de Louvain

Laurent Simar, Dr

Role: PRINCIPAL_INVESTIGATOR

Université Catholique de Louvain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Université Catholique de Louvain, CICN

Ottignies-Louvain-la-Neuve, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SAFFRUP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.